Skip to content

C1 Esterase Inhibitor

Published: July 26, 2026Updated: July 26, 2026

Haegarda is a brand-name C1 esterase inhibitor replacement therapy used for routine prevention of hereditary angioedema (HAE) attacks in adults and adolescents. Administered as a subcutaneous injection, typically twice weekly, it works by replacing the deficient C1 esterase inhibitor protein in patients with HAE to reduce the frequency and severity of swelling attacks.

Quick summary

Haegarda is a subcutaneous C1 esterase inhibitor injection used to prevent hereditary angioedema attacks in patients with C1 esterase inhibitor deficiency.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

RxNorm
1926819
Generic
Haegarda
Class
brand-name
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Routine prevention of hereditary angioedema (HAE) attacks in adults and adolescents with C1 esterase inhibitor deficiency. It is used as prophylaxis, not for treating acute attacks.

Haegarda contains human C1 esterase inhibitor, which replaces the deficient or dysfunctional protein in HAE patients. This restores the inhibition of the kallikrein-bradykinin pathway, reducing the production of bradykinin that causes the swelling, pain, and other symptoms of HAE attacks.

Haegarda is administered by subcutaneous injection, typically twice weekly. Common side effects may include injection site reactions, nasopharyngitis, and hypersensitivity reactions. Patients should be monitored for signs of hypersensitivity or thrombosis. This medication is for prophylactic use only and does not treat acute attacks—separate rescue medication should be available for breakthrough episodes.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy